



Orforglipron: An Integrated Review of an Oral Small-Molecule GLP-1 Receptor Agonist

Shruti M Aher^{1*}, Suyog I Jawale¹, Tanvi V Kulkarni

1. Department of Pharmaceutical Chemistry, [JSPM's Rajarshi Shahu College Of Pharmacy], [Pune, Maharashtra, 411033], India. (Affiliated to [Savitribai Phule Pune University])

ABSTRACT

Obesity and type 2 diabetes mellitus are chronic metabolic disorders with substantial cardiovascular, renal and metabolic consequences. Many established glucagon-like peptide-1 receptor agonists are peptide medicines administered by injection, creating practical barriers for patients. Orforglipron is an orally active, nonpeptide small-molecule glucagon-like peptide-1 receptor agonist developed to provide incretin-based metabolic efficacy without injections. An integrated review was prepared from two supplied 2026 sources: a Drug of the Month article emphasizing medicinal chemistry, receptor binding and regulatory milestones, and a comprehensive review synthesizing pharmacology, pharmacokinetics, clinical efficacy, safety and future directions. Findings were organized descriptively across structure, mechanism, pharmacokinetics, efficacy and tolerability. Orforglipron activates the glucagon-like peptide-1 receptor through a predominantly Gs-biased, transmembrane allosteric binding mode, increasing cyclic adenosine monophosphate signalling, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying and promoting satiety. Phase 2–3 evidence showed clinically meaningful reductions in glycated haemoglobin and dose-dependent weight loss of approximately 12–15% at higher doses in obesity. The principal tolerability limitation was gastrointestinal adverse effects, concentrated during dose escalation. Orforglipron represents a significant advancement in oral incretin pharmacotherapy. Long-term comparative effectiveness, cardiovascular and renal outcomes, real-world persistence and evidence in underrepresented populations remain important research gaps. [1,2,3,4,5,6,7,8,9,10]

Keywords: Incretin therapy; Medication adherence; Obesity management; Oral antidiabetic agents; Small-molecule agonists; Weight reduction

*Corresponding Author Name: Shruti M Aher
Received 1 October 2026, Accepted 21 October 2026

INTRODUCTION

Obesity and type 2 diabetes mellitus (T2D) are chronic metabolic disorders with overlapping pathophysiology and substantial cardiovascular, renal and metabolic consequences. Glucagon-like peptide-1 (GLP-1) receptor agonists have become an important therapeutic class because GLP-1 receptor activation improves glucose regulation while also reducing appetite, delaying gastric emptying and supporting weight reduction. However, many established GLP-1 receptor agonists are peptide medicines administered by injection, creating practical barriers for some patients. ^[13]

Orforglipron (LY3502970; OWL833; Foundayo) was developed to address this formulation and administration challenge. It is a nonpeptide, orally bioavailable GLP-1 receptor agonist that can be administered once daily. It was originally discovered by Chugai and licensed to Eli Lilly in 2018. An important feature of orforglipron is that it does not reproduce the peptide structure of endogenous GLP-1; instead, it uses a rigid polycyclic chemical architecture and engages a transmembrane/allosteric region of the GLP-1 receptor, demonstrating that a complex peptide-hormone receptor can be activated effectively by a small molecule while retaining oral activity. ^[1,9,10]

Although individual articles have described the medicinal chemistry of orforglipron and its clinical pharmacology separately, an integrated account connecting molecular design to clinical evidence remains limited. The present review therefore integrates two complementary 2026 sources: a Drug of the Month article in Trends in Pharmacological Sciences emphasizing structure, receptor interactions, development history and regulatory milestones, and a comprehensive review in the International Journal of Molecular Sciences covering pharmacology, pharmacokinetics, Phase 1–3 efficacy, safety, cardiometabolic biomarkers, limitations and future directions. The objective of this integrated review is to summarize the chemical structure, mechanism of action, pharmacokinetics, clinical efficacy, safety profile, clinical significance and future research directions of orforglipron, and to identify the evidence gaps that remain before its long-term clinical position can be defined. ^[1,2]

MATERIALS AND METHOD

This study is an integrated literature-based review prepared from two supplied 2026 sources used as the primary evidence base: Zhou, Li and Wang (Trends in Pharmacological Sciences, 2026), a concise drug-focused profile emphasizing medicinal-chemistry features, receptor-binding mode, development history, clinical positioning and the regulatory milestone; and Kansakar et al. (International Journal of Molecular Sciences, 2026), a comprehensive review synthesizing

pharmacology, pharmacokinetics, Phase 1–3 clinical efficacy, safety, cardiovascular biomarkers, limitations and future research directions. ^[1,2]

Data extraction and integration were performed descriptively. Information from the two sources was organized into prespecified domains: drug profile and development history; chemical structure and medicinal-chemistry features; mechanism of action; pharmacokinetics and pharmacodynamics; clinical efficacy in T2D; weight-loss and obesity outcomes; safety and tolerability; cardiometabolic effects; comparison with injectable GLP-1 receptor agonists; limitations; and future perspectives. Where the sources provided different levels of detail, the distinction was retained, and cross-trial comparisons were not treated as direct head-to-head evidence. Quantitative findings (e.g., glycated haemoglobin reductions, percentage weight loss, pharmacokinetic ranges) were reported as ranges as presented in the source review. Selected primary trial publications cited within the supplied sources were listed for reference context. No statistical pooling was performed; the analysis was qualitative and descriptive. ^[1,2]

RESULTS

The integrated findings are summarized below and presented objectively in Tables 1–3. Interpretation of these findings is reserved for the Discussion section.

Drug profile and development. Orforglipron is an orally active, nonpeptide small-molecule GLP-1 receptor agonist (LY3502970; OWL833; brand name Foundayo) developed for chronic weight management in adults with obesity or overweight with weight-related medical problems, with T2D evidence across Phase 2–3 studies. It is administered orally once daily without restrictions on food or water intake, in tablet strengths of 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. The development timeline reported in the supplied source is shown in Table 2.

Table 1: Orforglipron drug profile at a glance

Parameter	Integrated information from the supplied sources
Generic/ development name	Orforglipron; LY3502970; OWL833 ^[1,2]
Brand	Foundayo
Drug class	Oral, nonpeptide small-molecule GLP-1 receptor agonist
Primary target	Glucagon-like peptide-1 receptor (GLP-1R) ^[1,2]
Signalling profile	Predominantly Gs-biased; robust cAMP stimulation with limited beta-arrestin recruitment ^[9,10]
Route / dosing	Oral, once daily; no food or water restrictions
Molecular formula / weight	C48H48F2N10O5; 883.0 g/mol
Key efficacy	Meaningful HbA1c reduction and dose-dependent weight loss across Phase 2–3 studies ^[2,3,4,5,6]
Common adverse effects	Nausea, diarrhea, vomiting, constipation, dyspepsia, abdominal pain, eructation; headache/dizziness also reported ^[2,3,4,5,6]

Chemical structure and binding. Orforglipron is a highly functionalized polycyclic heterocycle (C₄₈H₄₈F₂N₁₀O₅; 883.0 g/mol) containing a conformationally constrained tetrahydro-pyrazolopyridine core. Being nonpeptide and lacking peptide bonds, it resists proteolytic degradation and supports oral exposure. Unlike peptide agonists, it interacts mainly with a transmembrane pocket, engaging extracellular loop 2 and the extracellular portions of transmembrane helices 1, 2, 3 and 7 — a site substantially overlapping that of the earlier small-molecule agonist Boc5. Ligand binding is associated with inward folding of the receptor extracellular domain to form a hydrophobic lid, outward movement of transmembrane helix 7 and an unusual extracellular kink in transmembrane helix 1. [9,10]

Table 2: Development timeline of orforglipron

Year	Milestone
2007	Discovery of Boc5, an early nonpeptidic/peptidomimetic GLP-1R agonist with in vivo activity [9]
2017	Chugai filed a PCT application for OWL833 [1]
2018	Chugai licensed OWL833 to Eli Lilly
2019–2020	Phase 1 clinical development [2,7,8]
2021–2022	Phase 2 clinical development [2,4,5,6]
2023–2026	Phase 3 clinical development [1]
1 Apr 2026	FDA approval milestone reported by the supplied Trends in Pharmacological Sciences source

Pharmacokinetics and pharmacodynamics. The comprehensive review reported rapid oral absorption, dose-proportional exposure and a half-life compatible with once-daily administration. Peak plasma concentrations were reached within approximately 2–4 hours and oral bioavailability was approximately 30–40%, with food intake having minimal impact on systemic exposure. Phase 1 studies reported half-lives broadly in the 24–38 hour range across healthy adults and participants with T2D. Pharmacodynamically, orforglipron enhanced glucose-dependent insulin secretion, reduced glucagon secretion and attenuated postprandial glucose excursions, with dose-dependent reductions in fasting glucose, HbA1c and body weight. [2,7,8]

Clinical efficacy. In T2D, a 26-week Phase 2 dose-finding study showed HbA1c reductions of approximately 0.9–1.6 percentage points across tested doses; another study reported reductions of approximately 1.0–1.5 percentage points over 12 weeks. The Phase 3 ACHIEVE-1 study in early T2D reported an average HbA1c reduction of approximately 1.4–1.6 percentage points over 40 weeks without significant hypoglycaemia. In obesity, Phase 2 studies showed approximately 7–10% mean body-weight reduction at 26 weeks at higher doses in participants with T2D, and the ATTAIN program reported sustained reduction over up to 72 weeks, with the highest doses producing approximately 12–15% mean weight loss in non-diabetic participants

and 10–12% in participants with T2D. Selected clinical findings are summarized in Table 3. [3,4,5,6]

Table 3: Selected clinical findings reported in the integrated evidence

Domain	Finding
Phase 2 T2D	HbA1c reductions approximately 0.9–1.6% at 26 weeks across dose groups; weight reduction approximately 4.5–9.8% in the summarized study ^[4]
ACHIEVE-1 (Phase 3)	Mean HbA1c reduction approximately 1.4–1.6% over 40 weeks in early T2D, with no significant hypoglycaemia reported ^[5]
ATTAIN program	Highest doses associated with approximately 12–15% mean weight loss in non-diabetic obesity and 10–12% in T2D populations over longer follow-up ^{3,6]}
Safety	Gastrointestinal events — especially nausea, diarrhea and vomiting — were the most common and generally occurred during dose escalation ^[2,4,5,6]
Pharmacokinetics	Tmax approximately 2–4 h; oral bioavailability approximately 30–40%; half-life broadly compatible with once-daily administration ^[2,7,8]

Safety and cardiometabolic effects. The dominant adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, eructation), generally dose-dependent, mild to moderate and concentrated during dose escalation. Adverse-event-related discontinuation was approximately 5–10% with orforglipron versus 2–4% with placebo. Hypoglycaemia was uncommon without insulin or insulin secretagogues. Pooled analyses were associated with reductions in systolic and diastolic blood pressure, LDL cholesterol, triglycerides and inflammatory markers, and an increase in HDL cholesterol, together with improvements in fasting insulin and HOMA-IR; hepatic and renal findings were reassuring in the available program. [2,4,5,6]

Comparison with injectable agonists. The supplied review reported cross-trial comparisons of HbA1c reduction of approximately 1.3–1.6% and weight loss of approximately 6–12% for orforglipron, versus approximately 1.5–1.8% and 12–15% respectively for semaglutide, and approximately 1.0–1.5% and 6–10% for liraglutide. These indirect comparisons derive from different populations, durations and endpoints. [2,3,13]

DISCUSSION

When the two supplied sources are considered together, orforglipron can be viewed as an example of translational continuity from molecular design to clinical medicine. The medicinal-chemistry article explains why the compound is orally active and how it engages the GLP-1 receptor through a distinctive transmembrane binding mode, while the comprehensive review

connects this mechanism to pharmacokinetics, glucose regulation, appetite control, weight reduction, safety and cardiometabolic biomarkers. The central innovation is not simply that orforglipron is a GLP-1 receptor agonist; rather, it demonstrates that a complex peptide-receptor target can be addressed with a small, orally active, nonpeptide molecule. The Gs-biased signalling profile, receptor conformational effects and favourable oral pharmacokinetics form a coherent pharmacological rationale for once-daily therapy. [1,2,9,10]

Clinically, the magnitude of HbA1c reduction and weight loss reported in the comprehensive review is sufficient to establish orforglipron as a serious member of the GLP-1 therapeutic landscape, and cross-trial comparisons suggest it can approach the efficacy range of established injectable agonists. However, these numbers should not be interpreted as a direct clinical ranking, because the studies were conducted in different populations with different durations, endpoints and dosing strategies. The key clinical question is whether the combination of efficacy, tolerability, convenience, adherence and cost produces better real-world outcomes, and the absence of direct head-to-head and real-world comparative studies remains an important gap. Similarly, the favourable cardiovascular biomarker changes are encouraging but remain surrogate markers; dedicated cardiovascular and renal outcome trials are required before reductions in blood pressure or lipids can be assumed to translate into fewer clinical events. [2,3,4,5,6,13]

The dominant tolerability limitation is gastrointestinal, and the observed weight reduction cannot be explained simply by such adverse effects: progressive weight loss continued after dose titration and patient-reported satiety supported an appetite-mediated mechanism, consistent with central GLP-1 pathway engagement. The glucose-dependent nature of insulinotropic signalling plausibly explains the low hypoglycaemia rate, and the nonpeptide format avoids peptide-drug immunogenicity, although long-term post-approval pharmacovigilance remains important. [2,7,8]

This review has limitations. Most completed trials lasted approximately 26–72 weeks, which does not establish durability over the years of treatment that chronic obesity and T2D may require. The relative contribution of weight-dependent and weight-independent glucose-lowering mechanisms requires further study using glucose clamps and advanced modelling; the precise neuronal populations underlying appetite effects and whether prolonged treatment protects beta-cell function in humans remain incompletely defined. Elderly patients, adolescents, people with severe obesity and patients with advanced renal or hepatic impairment were limited or underrepresented, restricting generalizability. Finally, as an integrated review of two supplied sources, this article inherits the scope and any biases of those sources. Future research should

include long-term cardiovascular and renal outcome trials, real-world adherence and persistence studies, formal combination trials with SGLT2 inhibitors, basal insulin and insulin-sensitizing therapies, extended-release formulations to reduce peak-related gastrointestinal symptoms, and next-generation oral incretin agents with optimized efficacy, receptor bias, tissue selectivity and tolerability.^[2]

CONCLUSION

Orforglipron (Foundayo) is a novel oral, nonpeptide GLP-1 receptor agonist whose development integrates medicinal chemistry, structural pharmacology and clinical metabolic medicine. Its rigid polycyclic structure enables oral bioavailability and a distinctive allosteric/transmembrane mode of receptor engagement, and predominantly Gs-biased signalling produces the expected incretin effects of glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and appetite reduction. The supplied clinical evidence demonstrates meaningful HbA1c lowering and clinically important weight reduction across T2D and obesity studies, with gastrointestinal adverse effects concentrated around dose escalation as the principal limitation. The oral once-daily route offers a major practical distinction from injectable GLP-1 therapies and may broaden acceptance among patients who prefer oral treatment. Nevertheless, long-term durability, direct comparisons with established and newer incretin therapies, cardiovascular and renal outcomes, real-world adherence, and efficacy and safety in underrepresented populations require further investigation. Orforglipron should therefore be regarded as a significant advancement in oral incretin pharmacotherapy, with its ultimate clinical value to be determined by longer-term and comparative evidence.^[1,2,9,10]

ACKNOWLEDGMENTS

The authors acknowledge the two supplied source articles (Zhou, Li and Wang, Trends in Pharmacological Sciences, 2026; Kansakar et al., International Journal of Molecular Sciences, 2026) as the primary evidence base for this integrated review.^[1,2]

Conflict of Interest: There is no conflict of interest for this study.

Funding: There was no specific funding for this review from any source.

REFERENCE

1. Zhou Q, Li G, Wang MW. Orforglipron (Foundayo) for adults with obesity. Trends Pharmacol Sci 2026; 47(8): 938-939.
2. Kansakar U, Jankauskas SS, Pande S, Mone P, Varzideh F, Santulli G. Orforglipron: a comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. Int J Mol Sci 2026; 27: 1409.

3. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. *N Engl J Med* 2023; 389: 877-888.
4. Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomized, dose-response, phase 2 study. *Lancet* 2023; 402: 472-483.
5. Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. *N Engl J Med* 2025; 393: 1065-1076.
6. Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). *Lancet* 2026; 406: 2927-2944.
7. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide GLP-1 receptor agonist: Phase 1a study. *Diabetes Obes Metab* 2023; 25: 2634-2641.
8. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide GLP-1 receptor agonist: Phase 1b study. *Diabetes Obes Metab* 2023; 25: 2642-2649.
9. Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. *Proc Natl Acad Sci USA* 2020; 117: 29959-29967.
10. Sloop KW, Cox AL, Wainscott DB, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. *Sci Transl Med* 2024; 16: eadp5765.
11. Dutta D, Nagendra L, Anne B, et al. Orforglipron, a novel non-peptide oral daily GLP-1 receptor agonist as an anti-obesity medicine: a systematic review and meta-analysis. *Obes Sci Pract* 2024; 10: e743.
12. Lutkemeyer C, Pasqualotto E, Ferreira ROM, et al. Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. *Arch Endocrinol Metab* 2024; 68: e230469.
13. Panou T, Gouveri E, Popovic DS, Papanas N. Orforglipron in type 2 diabetes mellitus and obesity: an overview. *Expert Rev Clin Pharmacol* 2025; 18: 883-898.

